Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Sawai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Sawai's Japan sales performance.

BeiGene announces positive phase 3 trial results for liver cancer treatment

BeiGene announces positive phase 3 trial results for liver cancer treatment

Japan. Last month, Novartis announced positive results from a phase 3 trial showing tislelizumab plus chemotherapy significantly improved OS for patients with advanced oesophageal cancer, regardless of PD-L1 status.

Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer

Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer The drug is currently approved in more than 70 markets around the world, including the US, EU Japan and China, to treat adults with non-metastatic castration-resistant prostate cancer (nmCRPC)

AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug

AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug Regulatory applications for Enhertu are also currently under review in Europe, Japan and several other countries based on the DESTINY-Breast04 results.

Amgen acquires ChemoCentryx in $3.7bn cash deal

Amgen acquires ChemoCentryx in $3.7bn cash deal The treatment is also approved in major markets outside the US, including the EU and Japan.

Sarepta to submit application for Duchenne muscular dystrophy gene therapy

Sarepta to submit application for Duchenne muscular dystrophy gene therapy The treatment has also been granted Rare Pediatric Disease (RPD) designation in the US, and Orphan Drug status in the US, the EU, Switzerland and Japan.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...